Expert Interview
Discussing the recent FDA approval for Medtronic’s Deep Brain Stimulation system for the treatment of primary dystonia
Ticker(s): MDTInstitution: Icahn School of Medicine at Mount Sinai
- Associate Professor of Neurology and Medical Director, Movement Disorders Neuromodulation and Brain Circuit Therapeutics
- Manages 30+ dystonia patients per year and 20 patients per week with Parkinson's disease
- Clinical focus is on the evaluation and management of adults and children with movement disorders, with particular focus on the use of deep brain stimulation, focused ultrasound and botulinum toxin injections.
How do you currently diagnose and manage primary dystonia, and which patient types do you typically consider for DBS referral today?
Added By: sara_adminWhat is the clinical significance of this FDA approval for Medtronic’s DBS system in primary dystonia?
Added By: sara_adminIn your experience, what outcomes are most important when evaluating DBS for dystonia (e.g., symptom reduction, functional improvement, disability scores, quality of life), and what magnitude/timeline of benefit is most realistic for patients?
Added By: sara_adminLooking ahead, what factors will most influence adoption of DBS for primary dystonia (e.g., identifying the right candidates earlier, surgeon/center expertise, payer coverage, long-term data, device features), and what remaining unmet needs still exist?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
